What one share of Adaptive Biotechnologies holds
Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.
Adaptive Biotechnologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.98 |
|---|---|
| Profit | −$0.41 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.15 |
| Cash and investments | $1.07 |
| Debt | $0.00 |
| Book value | $0.90 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $3.15 | −$3.50 | $0.20 | −$3.06 | — | −$18.42 |
| 2018 | $4.41 | −$3.67 | $0.50 | −$3.05 | — | −$20.10 |
| 2019 | $1.23 | −$1.01 | $0.16 | $2.81 | — | $4.56 |
| 2020 | $0.75 | −$1.11 | $0.14 | −$1.28 | — | $5.40 |
| 2021 | $1.10 | −$1.48 | $0.44 | −$1.81 | — | $4.27 |
| 2022 | $1.30 | −$1.40 | $0.11 | −$1.41 | — | $3.24 |
| 2023 | $1.18 | −$1.56 | $0.07 | −$1.16 | — | $2.13 |
| 2024 | $1.22 | −$1.08 | $0.02 | −$0.67 | — | $1.37 |
| 2025 | $1.83 | −$0.39 | $0.02 | −$0.32 | — | $1.42 |
Common questions about Adaptive Biotechnologies
How much does one share of Adaptive Biotechnologies earn?
Over the last 12 months, Adaptive Biotechnologies lost $0.41 for each share on $1.98 of sales.
Does Adaptive Biotechnologies pay a dividend?
Adaptive Biotechnologies didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Adaptive Biotechnologies’s book value per share?
Adaptive Biotechnologies’s book value is $0.90 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Adaptive Biotechnologies have?
Each share of Adaptive Biotechnologies has $1.07 of cash and investments and $0.00 of debt, as of June 30, 2026.
What is Adaptive Biotechnologies’s free cash flow per share?
−$0.15 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Adaptive Biotechnologies bought back shares?
Adaptive Biotechnologies’s share count rose about 1144% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.